Fecal microbiome analysis in patients with metabolic syndrome and type 2 diabetesOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined the gut microbiome of 79 adults in Galicia, Spain, classified by metabolic syndrome status and by glucose levels ranging from healthy to prediabetic to type 2 diabetic.
How was it studied?
Stool samples underwent 16S rRNA gene amplicon sequencing. Alpha diversity used Chao and Shannon indices, beta diversity used Bray-Curtis and Chao distances with permutational analysis of variance, and differential abundance used the LinDA method.
What did they find?
Metabolic syndrome patients had a higher Firmicutes/Bacteroidetes ratio with more Blautia, Tyzzerella, Streptococcus, and Ruminococcus callidus. Type 2 diabetes patients showed the opposite Bacteroidetes/Firmicutes ratio, less Actinobacteria, and more Dorea, Prevotella, Dialister invisus, Fusicatenibacter, and Coprococcus, while Eubacterium, Ligilactobacillus, and Acidaminococcus were more common in healthy or prediabetic individuals.
Why it matters
Shifts in the Firmicutes/Bacteroidetes ratio and specific enriched taxa may serve as microbial indicators of metabolic syndrome and type 2 diabetes pathology in this Spanish cohort.